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Open access under the ElHuman cysticercosis by Taenia crassiceps is rare although it is considered of zoonotic risk, especially to
immunocompromised individuals. Albendazole and praziquantel are widely used and effective in its
treatment. Their active forms inhibit the glucose uptake by the parasite and induce muscle contractions
that alter its glycogen levels interfering in the energetic metabolism of the parasite and leading to its
death. The aim of this study was to evaluate alterations in glycolysis, the tricarboxylic acid cycle and glu-
cose concentrations caused by low dosage treatments of the hosts with albendazole and praziquantel.
Therefore, T. crassiceps intraperitoneally infected mice were treated by gavage feeding with 5.75 or
11.5 mg/kg of albendazole and 3.83 or 7.67 mg/kg of praziquantel. The treated mice were euthanized
after 24 h and the cysticerci collected were morphologically classiﬁed into initial, larval or ﬁnal phases.
Concentrations of the organic acid produced and glucose were evaluated to detect alterations into the
glycolysis and the tricarboxylic acid cycle pathways through chromatography and spectrophotometry.
The low dosage treatment caused a partial blockage of the glucose uptake by the cysticerci in spite of
the non signiﬁcant difference between its concentrations. An activation of the tricarboxylic acid cycle
was noted in the cysticerci that received the treatment due to an increase in the production of citrate,
malate and a-ketoglutarate and the consumption of oxaloacetate, succinate and fumarate. The detection
of a-ketoglutarate indicates that the cysticerci which were exposed to the drugs after host treatment
present different metabolic pathways than the ones previously described after in vitro treatment.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Taenia crassiceps cysticercosis is a rare disease which occurs in
domestic animals mainly in USA and Western Europe (Hoberg
et al., 1999; Wünschmann et al., 2003; Ballweber, 2009). However
it represents a zoonotic risk especially to immunocompromised
individuals (Wünschmann et al., 2003). There are reports of cases
from France, Germany and England where cysticerci were found
in skeleton muscles, central nervous system and intra-ocular and
subcutaneous regions. The albendazole and praziquantel treat-
ments were effective in those cases (Klinker et al., 1992; Chermette
et al., 1995; François et al., 1998; Maillard et al., 1998; Heldwein
et al., 2006). However, there is little information on the mode of ac-
tion of these antihelminthic drugs on the main biochemical path-
ways used by the parasite.
Albendazole is a drug from the group of the benzimidazoles
which presents a rapid intestinal absorption after ingestion and
is rapidly converted into its active forms: the sulfoxide albendazole35 esq com 1a. Av. s/n, Setor
il. Fax: +55 62 3209 6363.
aud).
sevier OA license.and the sulfone albendazole, which are effective in vivo and in vitro
against the main species of intestinal nematodes and cestodes that
infect humans (Horton, 2000). In vertebrates, it induces the cyto-
chrome P450 complex activity, responsible for its metabolism
(Venkatesan, 1998). The average plasmatic half-life of its active
form is of approximately eight and a half hours, being eliminated
basically through urine (Venkatesan, 1998). Its active form inhibits
b-tubulin polymerization in the parasites interrupting the forma-
tion of microtubules and inhibiting the glucose capture, thereby
making the level of intracellular energy inadequate for helminth
survival through immobilization and then death due to insufﬁcient
energy production (Horton, 2000; Palomares et al., 2006).
On the other hand praziquantel is a compound well tolerated by
the human organism and due to its excellent pharmacological prop-
erties and is often used inmass chemotherapy treatment (Cioli et al.,
1995; Cioli and Pica-Mottoccia, 2003; Doenhoff et al., 2009). After
oral administration its metabolism is fast and its plasma half-life is
of about an hour. Generally, its metabolites have a longer plasma
half-life of about four hours and are represented mainly by mono-
hydroxylated praziquantel, with 4-hydroxycyclohexylcarbonyl as
the principal metabolite. These drug substances are eliminated
mostly through urine but also through bile and feces and, to a lesser
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toccia, 2003). Although often utilized, its action on cestodes has
yet to be fully elucidated. Cioli et al. (1995) described its action on
helminths of the Schistosoma genus. In these parasites, praziquantel
causesmuscle contraction, tegumental damage andmetabolic alter-
ations directly or indirectly related to the redistribution of the Ca2+
ions in parasite tissue.
Studies found in the literature describe ultra-structural altera-
tions (Palomares et al., 2004, 2006; Palomares-Alonso et al.,
2007) and structural alterations (Venkatesan, 1998; Cioli et al.,
1995; Cioli and Pica-Mottoccia, 2003; Horton, 2000) related to
the action of the active forms of these drugs. In vitro studies on
the energetic and respiratory metabolism of cysticerci described
glucose degradation pathways and the citric acid cycle (Corbin
et al., 1998) with an active electron transport chain (Del Arenal
et al., 2001). In vitro studies of the cysticerci exposed to praziquan-
tel and albendazole evaluated metabolic alterations in the excre-
tion/secretion of organic acids present in the glucose degradation
and in the citric acid cycle (Vinaud et al., 2007, 2008). Yet no
descriptions were found in the literature of the effects of drugs
in the main energy producing metabolic pathways in resident par-
asites. Therefore, the purpose of this study was to evaluate the
alterations in glycolysis, in the citric acid cycle and in the detection
of glucose in T. crassiceps cysticerci after the host treatment with
low doses of albendazole and praziquantel.2. Materials and methods
2.1. Maintenance of the T. crassiceps biological cycle
The biological cycle of T. crassiceps (ORF strain) has been main-
tained in the vivarium of the Instituto de Patologia Tropical e Saúde
Pública da Universidade Federal de Goiás (IPTSP/UFG) since 2002.
Ten initial phase cysticerci were inoculated in the intraperitoneal
cavity of 8–12 week old female BALB/c mice where they multiplied
by budding. Approximately 90 days after inoculation the animals
were euthanized and necropsied. The cysticerci were removed
from the intraperitoneal cavity, 10 initial phase specimens were
selected (Vinaud et al., 2008) and inoculated in other non-infected
mice for cycle continuation (Espindola et al., 2002; Vaz et al.,
1997).
The ethical principles for animal experimentation professed by
the Sociedade Brasileira de Ciência em Animais de Laboratório
(SBCAL) were followed and this study was authorized by the Com-
mittee for Ethical Research of the Federal University of Goias
(CoEp/UFG) (registration number 008/09).
The mice received daily care, acidiﬁed water and standard
rations.2.2. Mice infection and treatment
The BALB/c female mice were intraperitoneally inoculated with
10 initial phase T. crassiceps cysticerci (Vinaud et al., 2008), using
1 mL syringes. Thirty days after infection they were gavage treated
with low single doses of praziquantel (Merck) and albendazole
(Vitapan), 24 h after treatment they were euthanized for better
visual observation of the biochemical effects of the drugs on the
cysticerci.
The infected mice were divided into four groups, namely, group
A: consisting of 5 infected mice treated with a single dose of
5.75 mg/kg of albendazole; group B: consisting of 5 infected mice
treated with a single dose of 11.5 mg/kg of albendazole; group C:
consisting of 5 infected mice treated with a single dose of
3.83 mg/kg of praziquantel; group D: consisting of 5 infected mice
treated with a single dose of 7.67 mg/kg of praziquantel. A controlgroup was formed consisting of 5 infected mice that did not receive
treatment.
All the experiment was performed in quintuplicate. The doses
applied were determined according to the manufacturer’s recom-
mendation and then reduced to a level lower than necessary to
eliminate the parasite, as the purpose of the study was to access
the adaptability of the parasite to the drugs.
2.3. Cysticerci biochemical analysis
The cysticerci removed from the mice were classiﬁed macro-
scopically according to their evolutionary phase as initial, larval
and ﬁnal (Vinaud et al., 2007). The specimens were ﬁxed in liquid
nitrogen, homogenized with 12% perchloric acid as described by
Vinaud et al. (2007), and then the organic acids were extracted
for chromatographic analysis as described by Bezerra et al.
(1999) and Vinaud et al. (2007, 2008).
The organic acids were identiﬁed through high performance
liquid chromatography (HPLC) according to the previously deter-
mined retention time and calibration. Analyses were performed
on the acids present in the glycolytic pathway (pyruvate and
lactate) and in the citric acid cycle (oxaloacetate, citrate, a-keto-
glutarate, succinate, fumarate and malate) (Bezerra et al., 1999;
Vinaud et al., 2007, 2008).
2.4. Spectrophotometric analysis
The glucose concentrations were also analyzed from the cysti-
cerci after the perchloric acid procedure by dose response spectro-
photometry using a KoneLab 60i apparatus, according to the
commercial kit protocol, enzymatic method, Wiener lab.
2.5. Statistical analysis
The statistical analysis was performed using the Sigma Stat 2.3
program. Descriptive statistics were applied to determine the
mean and standard deviation and to evaluate the differences be-
tween the groups analyzed. The variables were tested for normal
distribution and homogeneous variance. As they presented normal
distribution, variance analysis was used. The differences noted
were considered signiﬁcant when p < 0.05.3. Results and discussion
This study evaluated the effect of the host treatment with low
doses of antihelminthic drugs on the energetic metabolism and
the glucose uptake of resident T. crassciceps cysticerci. Although
T. crassiceps cysticerci may be used as an experimental model for
Taenia solium cysticercosis studies due to their antigenical similar-
ity there are no studies reporting their biochemical similarity.
There are some studies reporting the effect of antihelminthic drugs
on T. solium cysticerci such as the report from Mahanty et al.
(2011) who demonstrated the in vitro effect of praziquantel and
albendazole on the excretion of alkaline phosphatase by T. solium
cysticerci showing that these drugs may affect more than one bio-
chemical pathway in order to kill this parasite. Also other effects on
morphological characteristics of the parasite have been described
such as the effect of praziquantel on the evagination of T. solium
cysticerci in vitro in contrast to ivermectin and oxfendazole (Ceder-
berg et al. 2011).
In the parasites from non treated hosts a greater concentration
of glucose was noted in larval phase cysticerci (p < 0.05). No statis-
tical differences were noted when comparing the groups treated
with both the drugs and the control group. In spite of exposure
to the drug, the dose applied was not sufﬁcient to totally block
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was also noted by Vinaud et al. (2008) in in vitro studies using low-
er drug doses. On the other hand, in the groups treated with prazi-
quantel there was an increase in the concentration of glucose
detected in the larval phase treated with 7.67 mg/kg in comparison
with the group treated with 3.83 mg/kg (p < 0.05). This is presum-
ably due to the drug mechanism that increases the availability of
muscle glycogen that is converted into glucose (Cioli et al., 1995;
Cioli and Picca-Mottoccia, 2003). There was not found in the liter-
ature the description of gluconeogenesis in cestodes as a mecha-
nism of survival when facing a hostile environment such as the
one with the presence of the antihelminthic drugs (Fig. 1).
The analysis of the organic acid production by T. crassiceps cys-
ticerci from hosts treated with 5.75 and 11.5 mg/kg of albendazole
and 3.83 and 7.67 mg/kg of praziquantel, evidenced the production
of organic acids indicative of glycolysis such as: lactate and pyru-
vate as well as organic acids indicative of the citric acid cycle such
as: oxaloacetate, citrate, a-ketoglutarate, succinate, fumarate and
malate (Tables 1 and 2, Fig. 2). No alterations were noted in the
lactate production. There were no signiﬁcant differences in the
comparisons with the control and treated groups. The different
drug concentrations did not alter the production of this organic
acid, probably because the glucose was used to produce energy
through the aerobic pathway (Del Arenal et al., 2005; Willms
et al., 2005), exactly the opposite in relation to previous studies
where T. crassiceps cysticerci were exposed in vitro to low doses
of albendazole and praziquantel and a smaller production of
lactate was noted (Vinaud et al., 2008). This is probably because
a larger availability of oxygen was observed in vitro than inside
the host as the activity of the citric acid cycle is directly propor-
tional to the amount of oxygen in the environment (Lehninger
et al., 2006). The host metabolism also transformed the drugs into
their active form favoring the aerobic pathway energy production
by the parasite. Vinaud et al. (2008) evaluated the in vitro lactate
secretion/excretion produced by glycolysis and no longer used by
the parasite, while this study evaluates de intracellular production
of this acid.
Meanwhile, pyruvate was not detected in the groups studied,
indicating that this acid was probably totally consumed in forming
mitochondrial and cytoplasmic malate, acetyl CoA and alanine asFig. 1. Gluconeogenesis pathway: the ﬁrst report of the oxaloacetate produced in
the citric acid cycle used as a substrate for the formation of glucose in T. crassiceps
(Pathway in bold is proposed from an adaption from Lehninger et al., 2006).described by Corbin et al. (1998) who detected the degradation
pathways of glucose and of the citric acid cycle in T. crassiceps
cysticerci.
The analysis of the oxaloacetate concentrations detected in the
control group showed that its production was higher in the larval
phase, followed by the initial and ﬁnal phases (p < 0.05). In the
groups treated with 5.75 and 11.5 mg/kg of albendazole and
3.83 mg/kg of praziquantel the same production pattern of oxalo-
acetate was noted in the phases (larval > initial > ﬁnal) (p < 0.05).
The larval phase presented the most metabolic activity since it is
the evolutive phase with the greatest cell replication rate and,
therefore, budding, requiring more energy use and consequently
active metabolic pathways with greater production of this acid
(Del Arenal et al., 2005; Willms et at., 2005) such as the phospho-
enolpyruvate carboxykinase enzyme pathway that converts phos-
phoenolpyruvate into oxaloacetate and the cytosolic malate
dehydrogenase and mitochondrial enzyme pathways that convert
malate into oxaloacetate (Corbin et al., 1998).
On the other hand, the oxaloacetate production noted in the ini-
tial phase in the control group was greater than that noted in the
same phase exposed to 11.5 mg/kg of albendazole (p < 0.05). This
is probably due to the fact that the albendazole mechanism of ac-
tion impedes glucose uptake. Therefore, the oxaloacetate produced
in the citric acid cycle may have been converted into glucose
through the gluconeogenesis pathway in an attempt to supply
the missing glucose as occurs in mammal hosts (Fig. 1) (Lehninger
et al., 2006). Although gluconeogenesis has been described in sev-
eral Protozoa parasites such as Plasmodium sp, Toxoplasma gondii
and Leishmania sp there are no reports of this capability in hel-
minths such as Taenia sp (Fleige et al., 2008; Olszewski et al.,
2010; Turner et al., 2011).
The citrate production in the control group proved signiﬁcantly
higher in the larval phase, followed by the initial and ﬁnal phases
(p < 0.05). In the groups treated with 5.75 and 11.5 mg/kg of alben-
dazole and 3.83 mg/kg of praziquantel, the citrate concentration
was higher in the larval phase than in the other evolutive phases
(p < 0.05). In the group treated with 7.67 mg/kg of praziquantel, a
higher production was noted in the larval phase than in the ﬁnal
phase (p < 0.05), while no difference was observed when compared
to the initial phase (p < 0.05). Considering the metabolic require-
ments of this evolutive phase, greater glucose degradation can be
seen and also an increase in metabolic pathway activity, such as
the citric acid pathway causing greater citrate production (Willms
et al., 2005). Vinaud et al. (2008) did not detect statistical differ-
ences in the secretion/excretion of oxaloacetate and citrate be-
tween the control groups and the groups exposed in vitro to
albendazole and praziquantel. Yet the dosage used by these
authors was smaller than that used in this study, probably not
affecting the aerobic metabolic pathways. The cysticerci exposed
to 5.75 and 11.5 mg/kg of albendazole and 3.83 mg/kg of prazi-
quantel presented an increase in aerobic energy production path-
ways resulting in a greater energy yield, since one of the modes
of action of these drugs consists in altering glucose uptake by the
parasites (Horton, 2000; Cioli et al., 1995; Cioli and Pica-Mottoccia,
2003). No descriptions in the literature were found stating that tae-
nids have a cytochrome P-450, although it has been described in
other helminths (Barret, 1998). Therefore, the parasite probably
did not manage to metabolize the drugs completely into their ac-
tive form using metabolic pathways in vitro that were different
from those used in resident parasites which are more dependable
on the biochemical pathways from the host.
The malate production in the control group proved to be greater
in the larval phase cysticerci followed by the initial and then ﬁnal
phase ones (p < 0.05). In the control group, the initial phase cysti-
cerci a greater production of malate was also noted when com-
pared to the same evolutive phases treated with 5.75 mg/kg of
Table 1
Mean concentrations ± SD of products from the energetic metabolism detected in Taenia crassiceps cysticerci (initial, larval and ﬁnal stages) treated with albendazole. Results in
pmol/L and mg/dL.
Control 5.75 mg/kg 11.5 mg/kg
Initial Larval Final Initial Larval Final Initial Larval Final
Glucose (mg/dL) 1.86 ± 1.00 26.50 ± 9.50 5.25 ± 2.50 1.80 ± 1.00 11.39 ± 4.75 2.83 ± 1.00 1.87 ± 1.00 13.59 ± 5.50 4.94 ± 3.00
Lactate 0.11 ± 0.04 0.21 ± 0.17 0.19 ± 0.19 0.02 ± 0.01 0.24 ± 0.048 0.02 ± 0.009 0.03 ± 0.009 0.18 ± 0.06 0.06 ± 0.01
Oxaloacetate 0.16 ± 0.13 0.28 ± 0.24 0.06 ± 0.02 0.09 ± 0.048 0.31 ± 0.12 0.087 ± 0.05 0.06 ± 0.043a 0.18 ± 0.09 0.12 ± 0.05
Citrate 1.77 ± 1.26 2.09 ± 1.72 0.41 ± 0.31 1.00 ± 0.32 3.41 ± 1.40 0.70 ± 0.40 0.71 ± 0.42 2.51 ± 1.73 0.73 ± 0.27
a-Ketoglutarate 0.12 ± 0.10 0.13 ± 0.12 0.03 ± 0.02 0.07 ± 0.04b 0.24 ± 0.05 0.06 ± 0.04 0.03 ± 0.01a 0.12 ± 0.08 0.06 ± 0.03
Succinate 0.93 ± 0.93 4.26 ± 4.26 1.68 ± 1.23 1.36 ± 0.50 7.53 ± 1.21 1.38 ± 0.80 0.64 ± 0.42 2.38 ± 0.92 1.54 ± 0.71
Fumarate 0.25 ± 0.19 0.34 ± 0.32 0.11 ± 0.06 0.17 ± 0.08 0.33 ± 0.16 0.12 ± 0.05 0.12 ± 0.09a 0.26 ± 0.002 0.11 ± 0.06
Malate 2.16 ± 1.64 3.15 ± 2.74 0.65 ± 0.42 1.29 ± 0.60a 5.49 ± 1.83 0.82 ± 0.60 0.66 ± 0.39a 4.17 ± 1.85 0.89 ± 0.72
a p < 0.05 compared to the same stage of the control group.
b p < 0.05 compared to the same stage of the other concentration tested.
Table 2
Mean concentration ± SD of products from the energetic metabolism detected in Taenia crassiceps cysticerci (initial, larval and ﬁnal stages) treated with praziquantel. Results in
pMol/L and mg/dL.
Control 3.83 mg/kg 7.67 mg/kg
Initial Larval Final Initial Larval Final Initial Larval Final
Glucose (mg/dL) 1.86 ± 1.00 26.50 ± 9.50 5.25 ± 2.50 2.95 ± 1.75 19.36 ± 8.00 5.95 ± 3.00 3.00 ± 2.00 40.00 ± 16.00 5.42 ± 3.00
Lactate 0.11 ± 0.04 0.21 ± 0.17 0.19 ± 0.19 0.02 ± 0.006 0.08 ± 0.04 0.03 ± 0.02 0.04 ± 0.004 0.14 ± 0.07 0.08 ± 0.02
Oxaloacetate 0.16 ± 0.13 0.28 ± 0.24 0.06 ± 0.02 0.05 ± 0.02 0.15 ± 0.07 0.08 ± 0.04 0.05 ± 0.005 0.15 ± 0.04 0.07 ± 0.03
Citrate 1.77 ± 1.26 2.09 ± 1.72 0.41 ± 0.31 0.69 ± 0.24 2.10 ± 1.18 0.61 ± 0.19 0.73 ± 0.46 2.49 ± 1.12 0.32 ± 0.13
a-Ketoglutarate 0.12 ± 0.10 0.13 ± 0.12 0.03 ± 0.02 0.03 ± 0.007a 0.11 ± 0.09 0.05 ± 0.02 0.03 ± 0.01a 0.11 ± 0.05 0.04 ± 0.02
Succinate 0.93 ± 0.93 4.26 ± 4.26 1.68 ± 1.23 1.07 ± 0.17 3.18 ± 2.50 1.99 ± 0.99 0.73 ± 0.35 2.50 ± 1.45 1.23 ± 1.07
Fumarate 0.25 ± 0.19 0.34 ± 0.32 0.11 ± 0.06 0.11 ± 0.08a 0.32 ± 0.27 0.09 ± 0.04 0.12 ± 0.08a 0.25 ± 0.20 0.04 ± 0.003
Malate 2.16 ± 1.64 3.15 ± 2.74 0.65 ± 0.42 0.71 ± 0.35a 2.81 ± 2.09 0.82 ± 0.37 0.72 ± 0.40a 2.93 ± 1.73 0.55 ± 0.38
a p < 0.05 compared to the same stage of the control group.
Fig. 2. Glycolysis pathway: T: substances with free transit across the mitochondrial membrane, 1: pyruvate kinase, 2: lactate dehydrogenase, 3: alanine aminotransferase, 4:
phosphoenolpyruvate carboxykinase pyruvate, 5: cytosolic malate dehydrogenase, 6: fumarase, 7: fumarate reductase, 8: mitochondrial malic enzyme, 9: cytosolic malic
enzyme, 10: pyruvate dehydrogenase complex, 11: acetoacetate decarboxylase, 12: mitochondrial malate dehydrogenase, 13: citrate synthase, 14: aconitase, 15: isocitrate
dehydrogenase, 16: a-ketoglutarate dehydrogenase, 17: succinyl-CoA synthetase. Enzymes 15 and 16 (bold) should be present as this is the ﬁrst report of a-ketoglutarate in
T. crassiceps (Pathway proposed from an adaptation from Corbin et al. (1998) and Lehninger et al. (2006)).
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treated with 11.5 mg/kg of albendazole and 3.83 mg/kg ofpraziquantel the malate production was greater in the larval phase
followed by the ﬁnal and then initial phases indicating that the
150 C.M. Fraga et al. / Experimental Parasitology 130 (2012) 146–151drugs at these concentrations inﬂuenced the activity of the cyto-
solic and mitochondrial malate dehydrogenase, cytosolic and mito-
chondrial malic enzyme and fumarase (Corbin et al., 1998).
The fumarate production proved higher in the larval phase cys-
ticerci than in the ﬁnal phase ones in the control group, yet no dif-
ference was noted when compared to the initial phase ones. In the
groups treated with 5.75 mg/kg of albendazole, 3.83 and 7.67 mg/
kg of praziquantel, the fumarate production was higher in the lar-
val phase cysticerci followed by the initial and ﬁnal phase ones.
This conﬁrms the detection of the fumarase enzyme that converts
mitochondrial malate into fumarate as noted by Corbin et al.
(1998) when studying the citric acid cycle of T. crassiceps cysticerci.
This study also showed that this reaction is reversible: the fuma-
rase enzyme can catalyze the malate formed from fumarate that
can be converted into oxaloacetate or even pyruvate in reversible
reactions catalyzed respectively by the mitochondrial malate
dehydrogenase enzyme and the mitochondrial malic enzyme
(Fig. 2). A greater production of fumarate was noted in the larval
phase as there is more cellular activity requiring a larger amount
of energy and, therefore, presenting more active metabolic
pathways.
The fumarate production by the initial phase cysticerci in the
control group was greater than that in the same evolutive phases
in the groups treated with 11.5 mg/kg of albendazole, 3.83 and
7.67 mg/kg of praziquantel. A greater production of succinate
was also noted in the larval phase cysticerci than in the initial
phase ones from the groups treated with 11.5 mg/kg of albenda-
zole and 3.83 mg/kg of praziquantel, yet no signiﬁcant difference
was detected when comparing this phases with the ﬁnal phase
cysticerci.
The concentration rates of both these organic acids, malate and
fumarate, are due to the mode of action of the drugs that impede
glucose uptake by the parasite. The citric acid cycle pathways are
probably activated and there is the consequent consumption of
metabolites such as malate and fumarate to form succinate as well
as to form FADH and NADH used in the electron transport chain to
generate ATP (Venkatesan, 1998; Horton, 2000; Dayan, 2003;
Mottier et al., 2006).
We would like to emphasize the detection of a-ketoglutarate in
all the groups studied since the presence of this organic acid had
not yet been described in T. crassiceps cysticerci, thereby conﬁrm-
ing that the citric acid cycle is complete in these parasites. The pro-
duction of a-ketoglutarate in the larval phase cysticerci in the
control group was signiﬁcantly higher than that in the other evol-
utive phases in the same group. A higher production of a-ketoglu-
tarate was also noted in the larval phase cysticerci in comparison
with the initial phase ones in the groups treated with 5.75 and
11.5 mg/kg of albendazole, 3.83 and 7.67 mg/kg of praziquantel.
It is likely that the a-ketoglutarate production was inﬂuenced by
the Ca2+ ion as occurs in mammals. The Ca2+ ions activate the iso-
citrate dehydrogenase, a-ketoglutarate dehydrogenase enzymes
and the pyruvate dehydrogenase complex, causing an increase in
the production of this acid (Lehninger et al., 2006). The a-ketoglu-
tarate detected may also have been produced by glutamate due to
the protein degradation, as seen in mammals, as an alternative
energy production pathway (Lehninger et al., 2006).
Other studies on the energetic and respiratory metabolism of T.
crassiceps cysticerci performed in vitro do not report the detection
of a-ketoglutarate (Vinaud et al., 2008; Corbin et al., 1998), indicat-
ing that the metabolism inside the hosts of this parasite may pres-
ent different pathways from those detected in vitro.
This study has concluded that T. crassiceps cysticerci exposed to
drugs inside the host present different metabolic adaptations in
relation to the patterns noted and described previously in vitro,
namely the production of a-ketoglutarate and gluconeogenesis.
This indicates a high level of metabolic interaction betweenparasite and host where the parasite uses the host’s pathways,
such as the cytochrome P-450 complex enzymes, as a form of met-
abolic complementation, as shown by the greater activity of the
drugs on the energetic and respiratory metabolism of the parasites.
Therefore, considering that the mode of action of the drugs is re-
lated to alterations in glucose incorporation, an increase was noted
in energetically more efﬁcient pathways, particularly in evolutive
phases that present greater cellular replication activity.Acknowledgments
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